1. Market Research
  2. > Orthostatic Intolerance - Pipeline Review, H2 2013

Orthostatic Intolerance - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Orthostatic Intolerance - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Orthostatic Intolerance - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Orthostatic Intolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Orthostatic Intolerance. Orthostatic Intolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Orthostatic Intolerance.
- A review of the Orthostatic Intolerance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Orthostatic Intolerance pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Orthostatic Intolerance.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Orthostatic Intolerance pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Orthostatic Intolerance - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Orthostatic Intolerance Overview 5
Therapeutics Development 6
Pipeline Products for Orthostatic Intolerance - Overview 6
Pipeline Products for Orthostatic Intolerance - Comparative Analysis 7
Orthostatic Intolerance - Therapeutics under Investigation by Universities/Institutes 8
Orthostatic Intolerance - Pipeline Products Glance 9
Clinical Stage Products 9
Orthostatic Intolerance - Products under Investigation by Universities/Institutes 10
Orthostatic Intolerance - Therapeutics Assessment 11
Assessment by Monotherapy Products 11
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Assessment by Therapeutic Class 18
Drug Profiles 20
acetazolamide sodium - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
atomoxetine hydrochloride - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
entacapone - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
mecamylamine hydrochloride - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
memantine hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
isosorbide dinitrate - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27



List of Tables

Number of Products under Development for Orthostatic Intolerance, H2 2013 6
Number of Products under Development for Orthostatic Intolerance - Comparative Analysis, H2 2013 7
Number of Products under Investigation by Universities/Institutes, H2 2013 8
Comparative Analysis by Clinical Stage Development, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Assessment by Monotherapy Products, H2 2013 11
Number of Products by Stage and Target, H2 2013 13
Number of Products by Stage and Mechanism of Action, H2 2013 15
Number of Products by Stage and Route of Administration, H2 2013 16
Number of Products by Stage and Molecule Type, H2 2013 17
Number of Products by Stage and Therapeutic Class, H2 2013 19



List of Figures

Number of Products under Development for Orthostatic Intolerance - Comparative Analysis, H2 2013 7
Number of Products by Top 10 Target, H2 2013 12
Number of Products by Stage and Top 10 Target, H2 2013 13
Number of Products by Top 10 Mechanism of Action, H2 2013 14
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 15
Number of Products by Top 10 Therapeutic Class, H2 2013 18
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 19



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.